半量替格瑞洛对高龄急性冠脉综合征并发慢性肾功能不全患者的疗效和安全性

被引:11
作者
张亮 [1 ]
袁铭 [1 ]
曹丰 [2 ]
机构
[1] 第四军医大学西京医院心血管内科
[2] 解放军总医院心内科
关键词
替格瑞洛; 剂量; 高龄; 急性冠脉综合征; 慢性肾功能不全;
D O I
10.13191/j.chj.2017.0077
中图分类号
R541.4 [冠状动脉(粥样)硬化性心脏病(冠心病)]; R692 [肾疾病];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
目的探讨半剂量替格瑞洛在高龄(>75岁)冠脉综合征(ACS)并发肾功能不全(CRI)患者中的远期疗效及安全性。方法入选ACS并发CRI的患者93例,分为替格瑞洛全剂量组(n=48例)及半剂量组(n=45)。全剂量组替格瑞洛负荷剂量180 mg,随之90 mg,2次/d,半剂量组负荷剂量90 mg,随之45 mg,2次/d。进行记录及临床随访12个月,比较两组患者主要不良心脑血管事件(MACCE))的发生率,出血事件的发生率,及其他不良反应的发生率。结果两组患者在基线临床资料如年龄、性别、吸烟史、高脂血症、高血压病、肝功能、左室射血分数(LVEF)及肾小球滤过率估计值(e GFR)等均无显著差异,而糖尿病患病率及ST抬高型ACS(STEACS)的发生率在两组之间有显著差异(P<0.05)。随访12个月发现,全剂量组和半剂量组的MACCE事件分别发生9例(19%)和6例(13%),两组之间差异无统计学意义。全剂量组和半剂量组出血事件分别发生16例(33%)和6例(13%),均为轻度出血,半剂量组出血事件显著少于全剂量组,有显著性统计学差异(P<0.05),无严重或者致死性出血的发生。呼吸困难在全剂量组和半剂量组的发生率分别为12例(25%)和9例(20%),呼吸困难均是轻度、可耐受、一过性的,两组之间无显著性统计学差异。结论半剂量的替格瑞洛对于高龄(>75岁)ACS并发CRI患者中和全剂量替格瑞洛有同样的疗效,并且有较好的安全性。
引用
收藏
页码:300 / 303
页数:4
相关论文
共 12 条
[1]
慢性肾功能衰竭患者凝血功能紊乱的发生机制 [J].
邓可 ;
钟玲 .
国际泌尿系统杂志, 2012, (02)
[2]
MDRD方程在我国慢性肾脏病患者中的改良和评估 [J].
全国eGFR课题协作组 .
中华肾脏病杂志, 2006, (10) :589-595
[3]
Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.[J].Long Zhe Guo;Moo Hyun Kim;Cai De Jin;Ju Yeong Lee;So Jeong Yi;Min Kyu Park;Young-Rak Cho;Tae-Ho Park.Platelets.2014, 6
[4]
Cardiovascular Mortality in Chronic Kidney Disease Patients Undergoing Percutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel [J].
Morel, Olivier ;
El Ghannudi, Soraya ;
Jesel, Laurence ;
Radulescu, Bogdan ;
Meyer, Nicolas ;
Wiesel, Marie-Louise ;
Caillard, Sophie ;
Campia, Umberto ;
Moulin, Bruno ;
Gachet, Christian ;
Ohlmann, Patrick .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (04) :399-408
[5]
Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial [J].
James, Stefan ;
Budaj, Andrzej ;
Aylward, Philip ;
Buck, Kristen K. ;
Cannon, Christopher P. ;
Cornel, Jan H. ;
Harrington, Robert A. ;
Horrow, Jay ;
Katus, Hugo ;
Keltai, Matyas ;
Lewis, Basil S. ;
Parikh, Keyur ;
Storey, Robert F. ;
Szummer, Karolina ;
Wojdyla, Daniel ;
Wallentin, Lars .
CIRCULATION, 2010, 122 (11) :1056-1067
[6]
Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non–ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease: A Report From the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network Registry.[J].Caroline S. Fox;Paul Muntner;Anita Y. Chen;Karen P. Alexander;Matthew T. Roe;Christopher P. Cannon;Jorge F. Saucedo;Michael C. Kontos;Stephen D. Wiviott.Circulation.2010, 3
[7]
Review of the treatment of acute coronary syndrome in elderly patients.[J].Maan Jokhadar.Clinical Interventions in Aging.2009, defa
[8]
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects [J].
Small, David S. ;
Kothare, Prajakti ;
Yuen, Eunice ;
Lachno, D. Richard ;
Li, Ying G. ;
Winters, Kenneth J. ;
Farid, Nagy A. ;
Ni, Lan ;
Jakubowski, Joseph A. ;
Salazar, Daniel E. ;
Thieu, Vivian T. ;
Payne, Christopher D. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (02) :127-135
[9]
Correlates of Bleeding Events Among Moderate- to High-Risk Patients Undergoing Percutaneous Coronary Intervention and Treated With Eptifibatide.[J].Ajay J. Kirtane;Gregory Piazza;Sabina A. Murphy;Daniela Budiu;David A. Morrow;David J. Cohen;Eric Peterson;Nasser Lakkis;Howard C. Herrmann;Theresa M. Palabrica;C. Michael Gibson.Journal of the American College of Cardiology.2006, 12
[10]
Impact of age on management and outcome of acute coronary syndrome: Observations from the global registry of acute coronary events (GRACE).[J].Alvaro Avezum;Marcia Makdisse;Frederick Spencer;Joel M. Gore;Keith A.A. Fox;Gilles Montalescot;Kim A Eagle;Kami White;Rajendra H. Mehta;Elias Knobel;Jean- Philippe Collet.American Heart Journal.2004, 1